Tissue Regenix Group (TRX)

 

TRX Share PerformanceMore

52 week high21.000 03/01/17
52 week low10.650 21/07/17
52 week change -5.500 (-26.83%)
4 week volume6,570,103 24/07/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Holding(s) in Company

RNS Number: 1729O Tissue Regenix Group PLC 16 August 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Tissue Rege...

Holding(s) in Company

RNS Number: 8288N Tissue Regenix Group PLC 11 August 2017 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii TISSUE REGENIX GROUP PLC 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voti...

Holding(s) in Company

RNS Number: 8286N Tissue Regenix Group PLC 11 August 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Tissue Rege...

Holding(s) in Company

RNS Number: 7070N Tissue Regenix Group PLC 10 August 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Tissue Reg...

Holding(s) in Company

RNS Number: 6927N Tissue Regenix Group PLC 10 August 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Tissue Rege...

Hardman Research: CellRight transforming US growth

RNS Number: 6752N Tissue Regenix Group PLC 10 August 2017 Hardman Research: CellRight transforming US growth CellRight Technologies: Transforming US growth prospects - TRX has a broad portfolio of regenerative medicine products developed from decellularised human and porcine soft tissues for the wound care, orthopaedics, and cardiac markets. Since ...

Holding(s) in Company

RNS Number: 6355N Tissue Regenix Group PLC 10 August 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Tissue Rege...

Director Deals - Tissue Regenix Group PLC (TRX)

Paul Devlin, Executive Director, bought 300,000 shares in the company on the 9th August 2017 at a price of 10.00p. The Dire...

Fundamental DataMore

EPS-1.27
Dividend yield0 %

Equity Research (TRX)

hardman & co
Tissue Regenix Group plc
10/08/2017
TRX has a broad portfolio of regenerative medicine products developed from decellularised human and porcine soft tissues for the wound care, orthopaedics, and cardiac markets. Since launch of...
hardman & co
Tissue Regenix Group Plc
17/03/2017
TRX has a broad portfolio of regenerative medicine products developed from decellularised human and porcine tissues for the wound care, orthopaedics, and cardiac markets. Sales of DermaPure have...
edison investment research
Tissue Regenix Group Plc
03/02/2017
Edison Investment Research is terminating coverage on Tissue Regenix Group (TRX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should...

Latest discussion posts More

  • Re: Hardman research

    On the other hand I didn't like the capitalisation of some of the R&D spend. I hope it relates to something patentable, or some capital equipment, otherwise it's just a con.
    15-Aug-2017
    Loldemort
  • Re: Hardman research

    I like the forecast of profitability by 2020 :-))) T P
    15-Aug-2017
    theprior
  • Re: Hardman research

    "Given that TRX?s US operations are based also in San Antonio, it is unsurprising that management intends to move its personnel into the CellRight building and to close its ...
    14-Aug-2017
    Loldemort

Users' HoldingsMore

Users who hold Tissue Regenix Group also hold..
LLOYDS GRP.32%
BP20%
SIRIUS MINERALS19%
TAYLOR WIMPEY19%
BT GROUP16%

Codes & Symbols

ISINGB00B5SGVL29
SymbolsTRX, LSE:TRX, TRX.L, TRX:LN, LON:TRX, XLON:TRX